Everolimus/nivolumab/pazopanib: Various toxicities: case report

February 2020
Reactions Weekly;2/8/2020, Vol. 1790 Issue 1, p110
Additionally, he developed pneumonitis and skin rash during treatment with nivolumab for metastatic clear cell type-RCC [ I routes not stated; not all dosages, durations of treatments to reactions onsets and outcomes stated i ]. Surveillance imaging revealed stable pulmonary nodules with a decrease in the size of the tumour at his nephrectomy site. On follow-up, 1.5 months after his hospital discharge, chest CT revealed unchanged pulmonary nodules with a significant improvement in ground-glass opacities in both lungs.


Related Articles

  • Everolimus.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p123 

    The article presents a case study of 42 year old man who had renal cell carcinoma (RCC) and when treated with drug everolimus, developed thrombocytopenia which is deficiency of platelets in the blood and eventually died due to RCC progression .

  • Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma. Rossetti, Sabrina; D'Aniello, Carmine; Iovane, Gelsomina; Scagliarini, Sarah; Laterza, Maria M.; De Vita, Fernando; Savastano, Clementina; Cartenì, Giacomo; Porricelli, Maria A.; Berretta, Massimiliano; Pisconti, Salvatore; Facchini, Gaetano; Cavaliere, Carla // Frontiers in Pharmacology;7/20/2017, p1 

    In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study,...

  • Update on acute respiratory distress syndrome. Moss, Marc // Cortlandt Forum;01/25/97, Vol. 10 Issue 1, p217 

    Presents an update on acute respiratory distress syndrome. Description of the disease; Incidence and prevalence of the disease; Clinical features of the disease; People at risk for the disease; Best mode of mechanical ventilation; Medical therapies; Fluid management; Disease outcome.

  • Therapeutic potential of mesenchymal stromal cells in the treatment of ARDS. Huppert, Laura A; Liu, Kathleen D; Matthay, Michael A // Transfusion;Feb2019, Vol. 59 Issue 2, p869 

    No abstract available.

  • The harm of high-frequency oscillatory ventilation (HFOV) in ARDS is not related to a high baseline risk of acute cor pulmonale or short-term changes in hemodynamics. Angriman, Federico; Ferreyro, Bruno L.; Donaldson, Lachlan; Cuthbertson, Brian H.; Ferguson, Niall D.; Bollen, Casper W.; Bachman, Thomas E.; Lamontagne, François; Adhikari, Neill K. J. // Intensive Care Medicine;Jan2020, Vol. 46 Issue 1, p132 

    The acute respiratory distress syndrome (ARDS) may encompass sub-populations that respond differently to treatments [[1]]. The hypothesized effect modifier (risk of RV failure) was defined by the acute cor pulmonale (ACP) score measured at baseline (pre-randomization) [[5]].

  • Bivalirudin/heparin: Haematological disorders: 13 case reports.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p80 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • Herpesviridae reactivation for poor outcome in ARDS patients with ECMO: criminal or witness? Huang, Huixue; He, Hangyong // Annals of Intensive Care;1/28/2020, Vol. 10 Issue 1, p1 

    We read with interest of the report by Hraiech and colleagues [[1]] about the I Herpesviridae i reactivation among non-immunocompromised critically ill patients with acute respiratory distress syndrome (ARDS) supported with extracorporeal membrane oxygenation (ECMO). Within all ARDS patients, by...

  • SARS Bulletin from Hong Kong: 30 March-4 April 2003. Cheng, V.C.C.; Peris, M.; Yuen, K.Y. // Clinical Infectious Diseases;4/15/2003, Vol. 36 Issue 8, piii 

    Presents a bulletin about severe acute respiratory syndrome (SARS) from infectious disease physicians affiliated with hospitals in Hong Kong, China. Confirmation that the virus was a coronavirus and that SARS patients demonstrated a specific antibody response against the infected cell lines.

  • structure-based drug design: A common cure for SARS? Ellis, Clare // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p509 

    Reports on a study conducted by Rolf Hilgenfeld and colleagues, which examined coronavirus main proteinase structure as a basis for design of drugs to fight severe acute respiratory syndrome (SARS). Crystal structure of the main proteinase; Characteristics of a peptide inhibitor called AG7088,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics